Healthcare provider profile · identity verified

Michael Denson, M.D.

Internal Medicine · BELLEVUE, WA · NPI 1417290891

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	595	163
Rosuvastatin Calcium	Rosuvastatin Calcium	330	105
Losartan Potassium	Losartan Potassium	304	100
Lisinopril	Lisinopril	247	74
Jardiance	Empagliflozin	243	60
Gabapentin	Gabapentin	241	66
Levothyroxine Sodium	Levothyroxine Sodium	194	51
Tamsulosin Hcl	Tamsulosin Hcl	189	58
Ozempic	Semaglutide	182	23
Amlodipine Besylate	Amlodipine Besylate	177	53
Omeprazole	Omeprazole	175	59
Metformin Hcl	Metformin Hcl	144	45
Trazodone Hcl	Trazodone Hcl	127	34
Alendronate Sodium	Alendronate Sodium	111	28
Hydrochlorothiazide	Hydrochlorothiazide	104	33
Metoprolol Succinate	Metoprolol Succinate	100	31
Simvastatin	Simvastatin	99	31
Pantoprazole Sodium	Pantoprazole Sodium	97	23
Metformin Hcl Er	Metformin Hcl	89	25
Furosemide	Furosemide	83	26
Fluticasone Propionate	Fluticasone Propionate	78	23
Allopurinol	Allopurinol	77	21
Clopidogrel	Clopidogrel Bisulfate	73	19
Spironolactone	Spironolactone	73	22
Duloxetine Hcl	Duloxetine Hcl	68	20
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	68	suppressed
Mirtazapine	Mirtazapine	65	12
Chlorthalidone	Chlorthalidone	62	19
Oxycodone Hcl	Oxycodone Hcl	60	13
Sertraline Hcl	Sertraline Hcl	59	15
Tramadol Hcl	Tramadol Hcl	58	suppressed
Atenolol	Atenolol	56	16
Pregabalin	Pregabalin	56	11
Metoprolol Tartrate	Metoprolol Tartrate	54	18
Famotidine	Famotidine	51	15
Albuterol Sulfate Hfa	Albuterol Sulfate	49	32
Potassium Chloride	Potassium Chloride	49	14
Escitalopram Oxalate	Escitalopram Oxalate	47	suppressed
Doxepin Hcl	Doxepin Hcl	45	13
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	42	16
Ezetimibe	Ezetimibe	41	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	suppressed
Estradiol	Estradiol	37	13
Venlafaxine Hcl Er	Venlafaxine Hcl	36	suppressed
Carvedilol	Carvedilol	34	suppressed
Yuvafem	Estradiol	33	13
Finasteride	Finasteride	32	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	23
Bupropion Xl	Bupropion Hcl	30	suppressed
Prednisone	Prednisone	30	19
Acyclovir	Acyclovir	29	suppressed
Alvesco	Ciclesonide	29	11
Bupropion Hcl Sr	Bupropion Hcl	29	11
Donepezil Hcl	Donepezil Hcl	29	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Topiramate	Topiramate	28	suppressed
Meloxicam	Meloxicam	27	12
Ondansetron Odt	Ondansetron	27	11
Propranolol Hcl	Propranolol Hcl	27	suppressed
Bupropion Hcl	Bupropion Hcl	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	11
Humulin N Kwikpen	Insulin Nph Human Isophane	26	suppressed
Ipratropium Bromide	Ipratropium Bromide	26	suppressed
Lorazepam	Lorazepam	26	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	26	23
Wixela Inhub	Fluticasone Propion/Salmeterol	26	suppressed
Buspirone Hcl	Buspirone Hcl	25	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	23	23
Doxycycline Monohydrate	Doxycycline Monohydrate	23	suppressed
Spiriva Respimat	Tiotropium Bromide	23	suppressed
Hydrocortisone	Hydrocortisone	22	13
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Cefdinir	Cefdinir	21	19
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Naltrexone Hcl	Naltrexone Hcl	20	suppressed
Terazosin Hcl	Terazosin Hcl	20	suppressed
Breyna	Budesonide/Formoterol Fumarate	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	19	suppressed
Torsemide	Torsemide	19	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	18	suppressed
Azelastine Hcl	Azelastine Hcl	17	suppressed
Dilt-Xr	Diltiazem Hcl	17	suppressed
Eliquis	Apixaban	17	suppressed
Latanoprost	Latanoprost	17	suppressed
Montelukast Sodium	Montelukast Sodium	17	suppressed
Humalog Kwikpen U-100	Insulin Lispro	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Lamotrigine	Lamotrigine	15	suppressed
Ciclopirox	Ciclopirox	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Humulin N	Insulin Nph Human Isophane	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Cartia Xt	Diltiazem Hcl	12	suppressed
Digoxin	Digoxin	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	11	11
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Retin-A	Tretinoin	11	suppressed
Temazepam	Temazepam	11	suppressed
Trimethoprim	Trimethoprim	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error